Last reviewed · How we verify
Essential tremor — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Inderal | propranolol | Generic (originally ICI/AstraZeneca) | Non-selective beta-blocker | Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2 | 1967-11-13 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally ICI/AstraZeneca) · 1 drug in Essential tremor
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Essential tremor:
- Essential tremor treatment updates — RSS
- Essential tremor treatment updates — Atom
- Essential tremor treatment updates — JSON
Cite this brief
Drug Landscape (2026). Essential tremor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/essential-tremor. Accessed 2026-06-10.
Related
- Essential tremor full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing